Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing.

Although the study did not reach statistical significance in primary and ancillary endpoints, the addition of trastuzumab provided a numerically high tumor response rate and a promising pathological regression compared to the control group: the tumor regression rate to grade Ia/Ib was obtained in 44.8% of patients [ 27 ].

also in 111,027 other papers